Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares Issued
Ratios

Entrada Therapeutics (TRDA) Leases: 2022-2025

Historic Leases for Entrada Therapeutics (TRDA) over the last 4 years, with Sep 2025 value amounting to $62.1 million.

  • Entrada Therapeutics' Leases fell 15.79% to $62.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $62.1 million, marking a year-over-year decrease of 15.79%. This contributed to the annual value of $71.1 million for FY2024, which is 12.73% down from last year.
  • As of Q3 2025, Entrada Therapeutics' Leases stood at $62.1 million, which was down 5.42% from $65.7 million recorded in Q2 2025.
  • In the past 5 years, Entrada Therapeutics' Leases registered a high of $88.3 million during Q2 2023, and its lowest value of $14.2 million during Q1 2023.
  • For the 3-year period, Entrada Therapeutics' Leases averaged around $69.5 million, with its median value being $73.8 million (2024).
  • In the last 5 years, Entrada Therapeutics' Leases slumped by 54.64% in 2023 and then soared by 454.21% in 2024.
  • Entrada Therapeutics' Leases (Quarterly) stood at $25.3 million in 2022, then surged by 221.59% to $81.5 million in 2023, then decreased by 12.73% to $71.1 million in 2024, then dropped by 15.79% to $62.1 million in 2025.
  • Its Leases stands at $62.1 million for Q3 2025, versus $65.7 million for Q2 2025 and $68.4 million for Q1 2025.